## CITATION REPORT List of articles citing

Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications

DOI: 10.1007/s40263-020-00741-5 CNS Drugs, 2020, 34, 795-800.

Source: https://exaly.com/paper-pdf/76825865/citation-report.pdf

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
51	The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. <i>Clinical Pharmacokinetics</i> , <b>2020</b> , 59, 1493-1500	6.2	9
50	Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing. <i>Cannabis and Cannabinoid Research</i> , <b>2021</b> ,	4.6	1
49	Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: A systematic review of clinical studies. <i>Pharmacotherapy</i> , <b>2021</b> , 41, 405-420	5.8	6
48	Pharmacokinetics and effects on arachidonic acid metabolism of low doses of cannabidiol following oral administration to horses. <i>Drug Testing and Analysis</i> , <b>2021</b> , 13, 1305-1317	3.5	6
47	Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research. <i>Neuropharmacology</i> , <b>2021</b> , 185, 108442	5.5	18
46	Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 637801	5.6	4
45	Cannabis, Cannabidiol Oils and Tetrahydrocannabinol-What Do Veterinarians Need to Know?. <i>Animals</i> , <b>2021</b> , 11,	3.1	7
44	Cannabidiol (CBD) repurposing as antibacterial: promising therapy of CBD plus polymyxin B against superbugs.		0
43	Delta-9-tetrahydrocannabinol and cannabidiol in psychosis: A balancing act of the principal phyto-cannabinoids on human brain and behavior?.		
42	Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 626010	5.6	12
41	Changes in Hepatic Phospholipid Metabolism in Rats under UV Irradiation and Topically Treated with Cannabidiol. <i>Antioxidants</i> , <b>2021</b> , 10,	7.1	3
40	Current trends on cannabidiol delivery systems: where are we and where are we going?. <i>Expert Opinion on Drug Delivery</i> , <b>2021</b> , 18, 1577-1587	8	1
39	Over the counter low-dose cannabidiol: A viewpoint from the ACRE Capacity Building Group. Journal of Psychopharmacology, <b>2021</b> , 2698811211035394	4.6	O
38	Comparative Study of Dissolution for Cannabidiol in EU and US Hemp Oil Products by HPLC. <i>Journal of Pharmaceutical Sciences</i> , <b>2021</b> , 110, 3091-3098	3.9	1
37	Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain. <i>Drugs</i> , <b>2021</b> , 81, 1513-1557	12.1	10
36	Contribution of the Adenosine 2A Receptor to Behavioral Effects of Tetrahydrocannabinol, Cannabidiol and PECS-101. <i>Molecules</i> , <b>2021</b> , 26,	4.8	1
35	Lipid-based formulations to increase cannabidiol bioavailability: In vitro digestion tests, pre-clinical assessment and clinical trial. <i>International Journal of Pharmaceutics</i> , <b>2021</b> , 609, 121159	6.5	4

34	Development and pharmacokinetic evaluation of a self-nanoemulsifying drug delivery system for the oral delivery of cannabidiol. <i>European Journal of Pharmaceutical Sciences</i> , <b>2021</b> , 168, 106058	5.1	3
33	The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson'd Disease: A Systematic Literature Review of Pre-Clinical Studies <i>Brain Sciences</i> , <b>2021</b> , 11,	3.4	О
32	A Phase I Trial to Determine the Pharmacokinetics, Psychotropic Effects, and Safety Profile of a Novel Nanoparticle-Based Cannabinoid Spray for Oromucosal Delivery <i>Medical Cannabis and Cannabinoids</i> , <b>2022</b> , 5, 9-19	4.1	
31	Cannabinoid-Based Medicine: Pharmacology and Drug Interactions. <b>2022</b> , 41-89		
30	Nutraceutical potential of industrial hemp (L.) extracts: physicochemical stability and bioaccessibility of cannabidiol (CBD) nanoemulsions <i>Food and Function</i> , <b>2022</b> ,	6.1	1
29	Cannabidiol-Loaded Mixed Polymeric Micelles of Chitosan/Poly(Vinyl Alcohol) and Poly(Methyl Methacrylate) for Trans-Corneal Delivery <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	2
28	Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli <i>Scientific Reports</i> , <b>2022</b> , 12, 6454	4.9	2
27	Development of amorphous solid dispersions of cannabidiol: Influence of the carrier, the hot-melt extrusion parameters and the use of a crystallization inhibitor. <i>Journal of Drug Delivery Science and Technology</i> , <b>2022</b> , 71, 103372	4.5	O
26	A Case Report of Subcutaneously Injected Liposomal Cannabidiol Formulation Used as a Compassion Therapy for Pain Management in a Dog <i>Frontiers in Veterinary Science</i> , <b>2022</b> , 9, 892306	3.1	О
25	Cannabinoids and the endocannabinoid system in fibromyalgia: A review of preclinical and clinical research. <b>2022</b> , 108216		1
24	Impact of Cannabidiol-Rich Hemp Extract Oil on Reconsolidation Disruption of Naturalistic Interoceptive Aversive Memory in Humans: Protocol for a Randomized Clinical Trial. SSRN Electronic Journal,	1	
23	Cannabidiol-Treated Ovariectomized Mice Show Improved Glucose, Energy, and Bone Metabolism With a Bloom in Lactobacillus. <i>Frontiers in Pharmacology</i> , 13,	5.6	O
22	Impact of cannabidiol-rich hemp extract oil on reconsolidation disruption of naturalistic interoceptive aversive memory in humans: Protocol for a randomized clinical trial. <i>Contemporary Clinical Trials</i> , <b>2022</b> , 106847	2.3	
21	Mechanism of Enhanced Oral Absorption of a Nano-Drug Delivery System Loaded with Trimethyl Chitosan Derivatives. Volume 17, 3313-3324		O
20	Mucosal Delivery of Cannabidiol: Influence of Vehicles and Enhancers. 2022, 14, 1687		О
19	Cannabidiol Reduces Short- and Long-Term High Glutamate Release after Severe Traumatic Brain Injury and Improves Functional Recovery. <b>2022</b> , 14, 1609		O
18	The Effectiveness and Safety of Cannabidiol in Non-seizure-related Indications: A Systematic Review of Published Randomized Clinical Trials.		О
17	Cannabidiol drug interaction considerations for prescribers and pharmacists.		O

16	Application of Oil-in-Water Cannabidiol Emulsion for the Treatment of Rheumatoid Arthritis.	Ο
15	Formulation of Nanomicelles Loaded with Cannabidiol as a Platform for Neuroprotective Therapy. <b>2022</b> , 14, 2625	1
14	Verifying in vitro -determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically based pharmacokinetic modelling.	0
13	Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration.	O
12	Pharmacokinetics of cannabidiol following single oral and oral transmucosal administration in dogs. 9,	0
11	Exploring the Potential of Cannabinoid Nanodelivery Systems for CNS Disorders. 2023, 15, 204	1
10	Cannabidiol Decreases Intestinal Inflammation in the Ovariectomized Murine Model of Postmenopause. <b>2023</b> , 11, 74	0
9	Pharmacokinetics and oral bioavailability of cannabidiol in horses after intravenous and oral administration with oil and micellar formulations.	O
8	Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance. <b>2023</b> , 24, 3125	1
7	Cannabidiol-Loaded Extracellular Vesicles from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Paclitaxel-Induced Peripheral Neuropathy. <b>2023</b> , 15, 554	О
6	Enhanced Skin Penetration of Cannabidiol Using Organosilane Particles as Transdermal Delivery Vehicles. <b>2023</b> , 15, 798	O
5	Metabolic, toxicological, chemical, and commercial perspectives on esterification of dietary polyphenols: a review. 1-40	O
4	CBD-Containing Liquids for e-Cigarettes: Formation of Psychotropic and Secondary Cannabinoids and Amount of CBD Surviving the Smoking Procedure. <b>2023</b> , 3, 258-272	0
3	Nanostructured Lipid Carriers Loaded with Cannabidiol Enhance Its Bioaccessibility to the Small Intestine. <b>2023</b> , 3, 210-221	O
2	Medical Cannabis Use Patterns for Sleep Disorders in Australia: Results of the Cross-Sectional CAMS-20 Survey. Volume 15, 245-255	0
1	Review of the oral toxicity of cannabidiol (CBD). <b>2023</b> , 113799	О